Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Notes Payables (2021 - 2023)

Historic Notes Payables for Indivior Pharmaceuticals (INDV) over the last 3 years, with Q4 2023 value amounting to $3.0 million.

  • Indivior Pharmaceuticals' Notes Payables changed 0.0% to $3.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $3.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.0 million for FY2023, which is 0.0% changed from last year.
  • As of Q4 2023, Indivior Pharmaceuticals' Notes Payables stood at $3.0 million, which was down 0.0% from $3.0 million recorded in Q4 2022.
  • Indivior Pharmaceuticals' Notes Payables' 5-year high stood at $3.0 million during Q4 2021, with a 5-year trough of $3.0 million in Q4 2021.
  • For the 3-year period, Indivior Pharmaceuticals' Notes Payables averaged around $3.0 million, with its median value being $3.0 million (2021).
  • Examining YoY changes over the last 5 years, Indivior Pharmaceuticals' Notes Payables showed a top increase of 0.0% in 2022 and a maximum decrease of 0.0% in 2022.
  • Over the past 3 years, Indivior Pharmaceuticals' Notes Payables (Quarter) stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023.
  • Its Notes Payables was $3.0 million in Q4 2023, compared to $3.0 million in Q4 2022 and $3.0 million in Q4 2021.